NICE approves new treatment for high-risk skin cancer

NICE |  September 2018 | NICE approves new treatment for high-risk skin cancer

Dabrafenib with trametinib is recommended, within its marketing 
authorisation, as an option for the adjuvant treatment of resected stage III
BRAF V600 mutation-positive melanoma in adults.

There are currently no adjuvant treatments available for stage III BRAF
V600 mutation-positive melanoma and there is a substantial risk of the
cancer returning and becoming incurable. Dabrafenib with trametinib is a
new adjuvant treatment aimed at curing the cancer by reducing the
likelihood that it will spread. It is therefore an important development in
managing stage III melanoma. (Source: NICE)

Of interest:

OnMedica  NICE approves new treatment for high-risk skin cancer

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s